Publications
-
A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2
A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2more -
UB-612 Multitope Vaccine targeting both Spike and Non-Spike Proteins of SARS-CoV-2 Provides Broad and Durable Immune Responses
UB-612 Multitope Vaccine targeting both Spike and Non-Spike Proteins of SARS-CoV-2 Provides Broad and Durable Immune ResponsesUB-612 Multitope Vaccine targeting both Spike and Non-Spike Proteins of SARS-CoV-2 Provides Broad and Durable Immune Responsesmore -
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptoms
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptomsIgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptomsmore -
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster UB-612
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster UB-612High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster UB-612more -
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernUB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concernmore -
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variantsA multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variantsmore -
Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine
Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide VaccinePotent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccinemore -
A Novel SARS-CoV-2 RBD-Protein/T Cell Peptide Multitope Vaccine Elicited Neutralizing Antibodies against Multiple Variants of Concerns: T cell Immunity and Protection Against Respiratory Infection in Mice and Non-Human Primates
A Novel SARS-CoV-2 RBD-Protein/T Cell Peptide Multitope Vaccine Elicited Neutralizing Antibodies against Multiple Variants of Concerns: T cell Immunity and Protection Against Respiratory Infection in Mice and Non-Human PrimatesA Novel SARS-CoV-2 RBD-Protein/T Cell Peptide Multitope Vaccine Elicited Neutralizing Antibodies against Multiple Variants of Concerns: T cell Immunity and Protection Against Respiratory Infection in Mice and Non-Human Primatesmore -
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment InterruptionEffect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruptionmore
